Home › Compound Library › Iron (Bisglycinate)

Iron (Bisglycinate)

Mineraloral · inferred

Essential for oxygen transport via hemoglobin. Bisglycinate form is gentle on the stomach with high absorption.

Projected serum levels — 18 mg, once daily

Iron (Bisglycinate)
Iron (Bisglycinate) modeled serum levels, 18 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 18 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 1.9 mg, trough ≈ 0.24 mg body load. Population-based estimate over 15 days for a 18 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Mineral
Route modeled
Oral
Model confidence
inferred
Half-life
6 h
Common dose
18 mg
Suggested maximum
45 mg/day
Reference dose range
9–45 mg (single dose)
Suggested cadence
once daily
Validated against
65 mg oral — Cmax 2 mg/L at 4 h

Documented interactions

  • danger
    Levothyroxine (Synthroid) + Iron (Bisglycinate) Protein binding

    Iron (Bisglycinate) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • warning
    Apigenin + Iron (Bisglycinate) Protein binding

    Apigenin may displace Iron (Bisglycinate) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Iron (Bisglycinate) Protein binding

    Aripiprazole (Abilify) may displace Iron (Bisglycinate) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Armour Thyroid (Desiccated Thyroid Extract) + Iron (Bisglycinate) Protein binding

    Iron (Bisglycinate) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Astaxanthin + Iron (Bisglycinate) Protein binding

    Astaxanthin may displace Iron (Bisglycinate) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Atomoxetine (Strattera) + Iron (Bisglycinate) Protein binding

    Atomoxetine (Strattera) may displace Iron (Bisglycinate) from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 153 modeled interaction pairings for iron (bisglycinate) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Daily iron supplementation for improving anaemia, iron status and health in menstruating women Low MS et al. · Cochrane Database of Systematic Reviews, 2016 DOI

    Cochrane review of 67 trials found daily iron supplementation effectively improved hemoglobin, reduced anemia risk, and improved exercise performance in menstruating women.

  2. Supplement-driven iron overload accelerates phenotypic aging via inflammatory biomarkers: Potential counteraction through anti-inflammatory or antioxidant diets. Li B, Ming Z, Wang Y, Zhang Y, Zhou R, Zhang C, Wu Y, Wang G, Xie H, Li Y, Li R · Redox biology, 2025 DOI

    This citation reports a primary research study involving Iron (Bisglycinate). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

  3. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR · Nutrients, 2022 DOI

    This citation reports a human clinical study involving Iron (Bisglycinate). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.